UnknownPhase 2

The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction

Egypt80 participantsStarted 2023-10-01

Plain-language summary

Diabetes mellitus people have a higher incidence of cardiovascular disease, and the results of cardiovascular events are worse. Heart failure and diabetes both have a worse prognosis, with a 1.5-2 times increased risk of death. Data from the literature have shown that MET lowers mortality by 14-35% in this patient population, which represents one-third of all HF patients with no increases in lactic acidosis incidence.

Who can participate

Age range40 Years – 74 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \- Inclusion criteria: * Age of 40 years to 74 years. * HFpEF (≥ 50%) * Written informed consent of the subject to participate in the study. * New York Heart Association functional class II-IV. * Body mass index ≥ 30 Kg/m2 Exclusion Criteria: * \- Exclusion criteria: * Patients with heart failure with reduced ejection fraction (\< 40%) * Age less than 40 and more than 74 * New York Heart Association functional class I * Body mass index \< 30 Kg/m2 * Diabetic patients or prior metformin user * Renal impairment * Known allergy to metformin * End- stage liver disease * Cancer * Pregnancy or lactation

What they're measuring

The change in the mean early diastolic mitral annular velocity (mean e'), at 3 and 6 months

Timeframe: baseline, 3 and 6 months

Trial details

NCT IDNCT05847244

SponsorSara ElAdawy

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-10

Contact for this trial

sara eladawy, PhD

01222124567 smeladway@msa.edu.eg

View on ClinicalTrials.gov More Diastolic Dysfunction trials